-
Tytuł:
-
Treatment of HCV in the Department of Corrections in the Era of Oral Medications.
-
Autorzy:
-
Sterling RK; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Cherian R; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Lewis S; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Genther K; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Driscoll C; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Martin K; 2 School of Pharmacy, Virginia Commonwealth University Health System, Richmond, VA, USA.
Goode MB; 2 School of Pharmacy, Virginia Commonwealth University Health System, Richmond, VA, USA.
Matherly S; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Siddiqui MS; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Luketic VA; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Stravitz RT; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Puri P; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Lee H; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Smith P; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Patel V; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
Sanyal AJ; 1 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA, USA.
-
Źródło:
-
Journal of correctional health care : the official journal of the National Commission on Correctional Health Care [J Correct Health Care] 2018 Apr; Vol. 24 (2), pp. 127-136. Date of Electronic Publication: 2018 Mar 22.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2021- : [New Rochelle, NY] : Mary Ann Liebert
Original Publication: Chicago, Ill. : The Commission, c1994-
-
MeSH Terms:
-
Prisons*
Antiviral Agents/*therapeutic use
Benzimidazoles/*therapeutic use
Fluorenes/*therapeutic use
Hepatitis C, Chronic/*drug therapy
Ribavirin/*therapeutic use
Uridine Monophosphate/*analogs & derivatives
Administration, Oral ; Adult ; Age Factors ; Aged ; Antiviral Agents/administration & dosage ; Benzimidazoles/administration & dosage ; Drug Combinations ; Drug Therapy, Combination ; Female ; Fluorenes/administration & dosage ; Genotype ; Humans ; Male ; Middle Aged ; Ribavirin/administration & dosage ; Sex Factors ; Socioeconomic Factors ; Sofosbuvir ; Sustained Virologic Response ; Treatment Outcome ; Uridine Monophosphate/administration & dosage ; Uridine Monophosphate/therapeutic use
-
Contributed Indexing:
-
Keywords: all oral direct-acting antiviral; correctional health care; hepatitis C treatment; telemedicine
-
Substance Nomenclature:
-
0 (Antiviral Agents)
0 (Benzimidazoles)
0 (Drug Combinations)
0 (Fluorenes)
0 (ledipasvir, sofosbuvir drug combination)
49717AWG6K (Ribavirin)
E2OU15WN0N (Uridine Monophosphate)
WJ6CA3ZU8B (Sofosbuvir)
-
Entry Date(s):
-
Date Created: 20180324 Date Completed: 20190506 Latest Revision: 20201209
-
Update Code:
-
20240104
-
DOI:
-
10.1177/1078345818762591
-
PMID:
-
29566611
-
Chronic hepatitis C virus (HCV) is widely prevalent in the Virginia Department of Corrections (DOC). However, sustained virologic response (SVR) with all oral direct-acting antiviral (DAA) therapy is unknown. HCV treatment was provided through telemedicine following guidelines of the American Association for the Study of Liver Diseases and Infectious Diseases Society of America. SVR12 in the DOC was compared in two control groups: privately insured and indigent patients receiving care in HCV treatment clinics by the same providers during the same time period. Of 220 DOC patients, 180 were started on therapy (158 genotype [GT] 1, 15 GT2, and 10 GT3). SVR12 data on GT1 patients who received ledipasvir/sofosbuvir with or without ribavirin (RBV) were 96%, similar to our indigent (95%) and private clinic (93%) patients despite differences in age, gender, treatment experience, FIB-4, and use of RBV. Multiple logistic regression of GT1 patients identified lower FIB-4 ( p = .008) and treatment clinic ( p = .01) as independent predictors of SVR12. HCV treatment in the DOC by telemedicine with DAA is not only feasible but has a very high SVR12 similar to published trials.
